MedTrace Logo

Study of the Safety and Immunogenicity of NasoVAX Extension

NCT03760549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2025-06-19

No results posted yet for this study

Summary

This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.

Conditions

Interventions

DRUG

Subjects were administered NasoVAX high dose

NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo

Sponsors & Collaborators

  • Altimmune, Inc.

    lead INDUSTRY

Principal Investigators

  • Peta-Gay Jackson-Booth, MD · Study Principal Investigator

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2019-02-18
Completion
2019-02-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03760549 on ClinicalTrials.gov